Hemosol Receives Receipt for Final Prospectus
June 20 2005 - 8:02PM
PR Newswire (US)
Hemosol Receives Receipt for Final Prospectus TORONTO, June 20
/PRNewswire-FirstCall/ -- Hemosol Corp. (NASDAQ:HMSLDNASDAQ:
TSX:NASDAQ:HML) today announced that it has received a final
receipt from the Ontario Securities Commission for its long form
prospectus. This prospectus qualifies for distribution the common
shares and warrants underlying the special warrants sold to
investors by way of Hemosol's previously announced private
placement on April 8, 2005. The special warrants will be deemed
exercised at 5:00 p.m. (EST) on June 27, 2005. About Hemosol
Hemosol is a biopharmaceutical company focused on the development
and manufacturing of biologics, particularly blood-related
proteins. Hemosol has a broad range of novel therapeutic products
in development, including oxygen therapeutics and protein-based
therapeutics to treat certain infectious diseases, cancers and
anemia. For more information visit Hemosol's website at
http://www.hemosol.com/. The Common Shares are listed on the NASDAQ
Stock Market under the trading symbol "HMSLD" and on the Toronto
Stock Exchange (TSX) under the trading symbol "HML". Certain
statements concerning Hemosol's future prospects are "forward-
looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995 and other applicable
securities legislation. There can be no assurances that future
results will be achieved, and actual results could differ
materially from forecasts and estimates. Important factors that
could cause actual results to differ materially from forecasts and
estimates include, but are not limited to: Hemosol's ability to
successfully implement the Cascade technology and commercialize
products derived there from; Hemosol's ability to obtain additional
financing which is critical to the implementation of the Cascade
technology and to Hemosol's continued viability as a going concern;
Hemosol's ability to obtain regulatory approvals for its products;
Hemosol's ability to successfully complete clinical trials for its
products; Hemosol's ability to enter into satisfactory arrangements
for the supply of materials used in its manufacturing operations
and the sale of resulting products to customers; technical,
manufacturing or distribution issues; the competitive environment
for Hemosol's products and services; the degree of market
penetration of Hemosol's products; Hemosol's ability to attract and
retain clients for its bio-manufacturing services; the risk that
Hemosol may not become profitable; and other factors set forth in
filings with Canadian securities regulatory authorities and the
U.S. Securities and Exchange Commission. These risks and
uncertainties, as well as others, are discussed in greater detail
in the filings of Hemosol with Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission.
Hemosol makes no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances after the
date any such statement is made. DATASOURCE: Hemosol Corp. CONTACT:
Jason Hogan, Investor & Media Relations, (416) 361-1331, (800)
789-3419, (416) 815-0080 fax, , http://www.hemosol.com/; Archived
images on this organization are searchable through CNW Photo
Archive website at http://photos.newswire.ca/. Images are free to
accredited members of the media. To request a free copy of this
organization's annual report, please go to http://www.newswire.ca/
and click on reports@cnw.
Copyright
Hemosol (NASDAQ:HMSLD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hemosol (NASDAQ:HMSLD)
Historical Stock Chart
From Jul 2023 to Jul 2024